Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Sees Significant Growth in Short Interest

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) was the target of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 736,300 shares, a growth of 462.1% from the January 31st total of 131,000 shares. Based on an average daily trading volume, of 1,410,000 shares, the short-interest ratio is presently 0.5 days. Approximately 5.9% of the company’s shares are short sold.

Cyclo Therapeutics Price Performance

Shares of CYTH traded up $0.00 during mid-day trading on Thursday, reaching $0.77. 98,177 shares of the company’s stock traded hands, compared to its average volume of 2,388,379. The stock’s 50-day moving average is $0.77 and its two-hundred day moving average is $0.76. Cyclo Therapeutics has a 12 month low of $0.55 and a 12 month high of $1.79. The stock has a market cap of $25.35 million, a P/E ratio of -0.86 and a beta of -0.49.

Hedge Funds Weigh In On Cyclo Therapeutics

An institutional investor recently bought a new position in Cyclo Therapeutics stock. Two Sigma Securities LLC bought a new stake in shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 42,541 shares of the company’s stock, valued at approximately $25,000. Two Sigma Securities LLC owned 0.15% of Cyclo Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 68.55% of the company’s stock.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.